GET DAILY SIGNALSWhy Is TG Therapeutics (TGTX) Stock Down -4.53% Today?
Key Takeaways
- TGTX shares fell 4.53% on Monday, trading near $57.12, down from the prior session's close of $59.83.
- The decline followed a mixed third-quarter earnings report that showed a modest earnings-per-share miss offsetting stronger-than-expected revenue.
- Investors weighed an EPS of $0.35, just below the $0.37 consensus, even as revenue of $259.94 million topped the $245.47 million estimate.
- Profit-taking also pressured the stock after a strong run that has kept shares near their 52-week high of $63.60.
- The company reaffirmed its growth trajectory by raising full-year global revenue guidance to $1 billion for 2026.
- Traders are watching analyst reactions to the results and any updates on the BRIUMVI pipeline and subcutaneous formulation.
- For more detail on valuation, results, and outlook, explore Price Targets, Earnings, and Forecast pages.
- Discover the strongest-performing automated strategies of the moment on the Trending AI Robots page.
Opening Summary
TG Therapeutics, Inc. (TGTX), a commercial-stage biopharmaceutical company best known for BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis, saw its shares slide 4.53% in Monday's session. The stock changed hands near $57.12, down $2.71 from Friday's close of $59.83. The move lower came after the company reported third-quarter financial results that beat on revenue but fell short on earnings, triggering profit-taking in a stock that has been trading near multi-year highs.
Earnings Results and Guidance
The primary catalyst behind Monday's decline was the company's third-quarter earnings release. TG Therapeutics reported earnings of $0.35 per share, narrowly missing the consensus estimate of $0.37. At the same time, revenue of $259.94 million exceeded analysts' expectations of $245.47 million, driven by continued strength in U.S. BRIUMVI net sales of roughly $233 million.
Despite the top-line beat, the modest bottom-line miss appeared to weigh on sentiment. Management also addressed the outlook by raising full-year 2026 global revenue guidance to approximately $1 billion, underscoring confidence in BRIUMVI's commercial momentum less than four years after launch. The market's negative reaction suggests investors had positioned for a cleaner earnings beat given the stock's elevated valuation and recent run-up.
Profit-Taking Near 52-Week Highs
Beyond the headline numbers, technical positioning likely amplified the decline. TGTX entered the session trading near its 52-week high of $63.60, following a powerful rally that has lifted the shares significantly over the past year. When a stock sits at stretched levels, even a slightly mixed earnings report can trigger a wave of profit-taking as short-term traders lock in gains. The combination of an EPS miss and elevated expectations created a natural setup for selling pressure.
Market Context and Trading Activity
Trading activity was elevated as investors digested the results, consistent with the heavier volume typically seen on earnings days. The move reflected company-specific news rather than a broad biotech or healthcare selloff, as the earnings-driven reaction was the dominant factor. The stock remained above its 50-day moving average near $55.80 and its 200-day moving average near $44.50, indicating that the pullback, while meaningful, has not yet disrupted the longer-term uptrend. The shares also remain well within their 52-week trading range of roughly $26.76 to $63.60.
What Comes Next for TGTX
Investors will be watching how Wall Street analysts respond to the mixed quarter, particularly given a consensus rating of Moderate Buy and price targets that generally sit above current trading levels. Attention will also focus on the BRIUMVI pipeline, including the potential approval of a consolidated IV initiation dose targeted for mid-2027 and the subcutaneous formulation, for which Phase III results are expected around year-end or early 2027. Key risks include competitive dynamics in the anti-CD20 multiple sclerosis market, the timing of regulatory decisions, and the possibility that investor expectations remain elevated following the stock's strong performance.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies that are performing particularly well under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Only the strongest performers are featured in this section, giving traders a focused view of the strategies showing the most momentum right now. Explore the page to see which AI-driven approaches are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TGTX in upward trend: 10-day moving average crossed above 50-day moving average on October 30, 2026
The 10-day moving average for TGTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on TGTX as a result. In 67 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for TGTX just turned positive on October 27, 2026. Looking at past instances where TGTX's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
TGTX moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in 253 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 177 of 226 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for TGTX moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 35 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 62 cases where TGTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
TGTX broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.159) is normal, around the industry mean (3.498). P/E Ratio (19.551) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.136) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement